Trending NewsTrending NewsNASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.75 +0.07 (+9.66%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenaya Therapeutics Stock (NASDAQ:TNYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.67▼$0.7550-Day Range$0.49▼$0.8852-Week Range$0.36▼$4.01Volume2.06 million shsAverage Volume2.75 million shsMarket Capitalization$121.42 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read More Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 566th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.60% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 4.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.60% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 4.67%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment0.37 News SentimentTenaya Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for TNYA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows10 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,307.00 in company stock.Percentage Held by Insiders48.65% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesWhat is Leerink Partnrs' Forecast for TNYA FY2025 Earnings?August 12 at 2:33 AM | americanbankingnews.comWilliam Blair Issues Optimistic Estimate for TNYA EarningsAugust 12 at 2:15 AM | americanbankingnews.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 12 at 2:00 AM | Brownstone Research (Ad)Tenaya Therapeutics (NASDAQ:TNYA) Upgraded by Wall Street Zen to "Hold" RatingAugust 11 at 2:31 AM | americanbankingnews.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comTenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $1.43 at the beginning of 2025. Since then, TNYA stock has decreased by 48.7% and is now trading at $0.7340. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Wednesday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional investors of Tenaya Therapeutics include Geode Capital Management LLC (0.76%), CWM LLC (0.06%) and Savant Capital LLC (0.05%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa and Chihiro Saito. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/12/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Tenaya Therapeutics$6.25 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside+800.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-93.83% Return on Assets-75.66% Debt Debt-to-Equity RatioN/A Current Ratio6.00 Quick Ratio6.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book0.65Miscellaneous Outstanding Shares162,980,000Free Float83,688,000Market Cap$113.11 million OptionableOptionable Beta3.01 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:TNYA) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.